

Ecallantide TFA

Cat. No.:	HY-108814A
Molecular Formula:	$C_{305}H_{442}N_{88}O_{91}S_8 \cdot xC_2H_3O_2$
Sequence:	Glu-Ala-Met-His-Ser-Phe-Cys-Ala-Phe-Lys-Ala-Asp-Asp-Gly-Pro-Cys-Arg-Ala-Ala-His-Pro-Arg-Trp-Phe-Phe-Asn-Ile-Phe-Thr-Arg-Gln-Cys-Glu-Glu-Phe-Ile-Tyr-Gly-Gly-Cys-Glu-Gly-Asn-Gln-Arg-Phe-Glu-Ser-Leu-Glu-Glu-Cys-Lys-Lys-Met-Cys-Thr-Arg-Asp (Disulfide bond:Cys1-Cys6, Cys2-Cys4, Cys3-Cys5) <small>EAMHSFCFAFKADDGPCRAAHPRWFFNIFTRQCEEFYGGCEGNQNRFSLEECKMCTRD (Disulfide bond Cys1-Cys6, Cys2-Cys4, Cys3-Cys5) (TFA salt)</small>
Sequence Shortening:	EAMHSFCFAFKADDGPCRAAHPRWFFNIFTRQCEEFYGGCEGNQNRFSLEECKMCTRD (Disulfide bond:Cys1-Cys6, Cys2-Cys4, Cys3-Cys5)
Target:	Kallikrein
Pathway:	Immunology/Inflammation
Storage:	Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

BIOLOGICAL ACTIVITY

Description

Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide may be used to prevent acute attacks of angioedema^[1].

REFERENCES

[1]. Martello JL, et al. Ecallantide for treatment of acute attacks of hereditary angioedema. Am J Health Syst Pharm. 2012 Apr 15;69(8):651-7. [Content Brief]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA